Eli Lilly reduces costs of Zepbound through its LillyDirect platform

Eli Lilly on Monday announced new price cuts for its popular weight-loss drug Zepbound, broadening access for patients and greater use of the company’s digital healthcare platform, LillyDirect.

Single-dose vials of Zepbound purchased through the Zepbound Self Pay Journey program at LilyDirect will now cost $299 per month, down from $349 for patients with a valid prescription.

The price of a 5 mg dose will also drop from $499 to $399 per month. All other approved doses will cost $449 a month, Eli Lilly said.

LillyDirect, which launched in early 2024, allows certain consumers who are uninsured or do not have adequate coverage to access ZepBound and Monjaro directly from Eli Lilly through its ZepBound Self Pay Journey program.

Trump announces deal with drug makers to lower prices on weight loss drugs

Single-dose vials of Zepbound will now cost $299 per month. (Shelby Knowles/Bloomberg via Getty Images/Getty Images)

According to the pharmaceutical giant, regular prices per month if not purchased through the Zepbound Self-Pay Journey program are $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, $1,049 for 15 mg.

Vegovi, Ozempic: barriers to accessing these weight loss drugs

The move comes less than a month after Eli Lilly announced plans to reduce prices of its Zepbound multi-dose pens, although it is still subject to approval by the Food and Drug Administration (FDA). Starting in April 2026, Medicare patients will not have to pay more than $50 a month for Zepbound, sold in a multi-dose pen, and Lilly’s once-a-day weight-loss pill orforglipron, as long as both drugs are approved by the FDA.

Eli Lilly rival Novo Nordisk makes its own weight loss drugs, Vegovy and Ozempic. (Shelby Knowles/Bloomberg via Getty Images)

For self-pay patients, the Zepbound Multi-Dose Pen will be available for a minimum dose of $299, with additional doses available for up to $449. When patients refill their multi-dose pain prescriptions on the LilyDirect digital health platform, they will pay no more than $449. The company previously said that orforgaliprone will be available starting at $149 with the lowest dose and going up to $399 with additional doses.

Major health insurers are cutting back on offering Medicare benefits in 2026

Eli Lilly and Novo Nordisk have launched their own direct-to-consumer platforms that aim to expand patient access by limiting the barriers new patients face. While both companies say these platforms will help new patients gain access to their medicines, they will also give each company a competitive edge.

Get Fox Business by clicking here

Novo Nordisk launched its platform, NovoCare Pharmacy, in March to allow patients who couldn’t afford the standard list price or lack insurance coverage for the weight-loss drugs Vegov and Ozempic.